GLP-1R agonists therapy for type 2 diabetes

Zhou, Bilan; Peng, Anlin; Gong, Hao; Huang, Kun

doi:10.1007/s11859-014-0974-8

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The novel physiological effects of GLP-1(28-36)amide, such as inhibiting weight gain and attenuating glucose levels, and showing effects on β cells and hepatocytes, suggest that GLP-1(28-36)amide could be highly attractive as an add-on treatment in therapy of T2DM. On the other hand, the unique mitochondrial targeting property of GLP-1(28-36)amide is rather different form its precursor GLP-1 or GLP-1R agonists [ 53 ], such phenomenon will be of great interest to be further understood. Further studies to define whether GLP-1(28-36)amide activates a new receptor or possesses other action modes are also necessary.…”

Section: Summary and Disccssionmentioning

confidence: 99%

GLP-1(28-36)amide, a Long Ignored Peptide Revisited

Zhou

Peng

et al. 2014

TOBIOCJ

Self Cite

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1), which has been extensively applied for treating type 2 diabetes mellitus (T2DM), is an incretin hormone that regulates glucose homeostasis. GLP-1(28-36)amide, a C-terminal nonapeptide (FIAWLVKGRamide) of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide has long been regarded as a metabolically inactive byproduct, however, recent findings reveal that GLP-1(28-36)amide plays multiple novel roles in ameliorating hepatic metabolism, protecting β cells, improving glucose disposal and inhibiting weight gain. Here, we summarize the latest progress on the effects of GLP-1(28-36)amide with a focus on its roles in regulating the Wnt and mitochondrial-mediated signaling pathways.

show abstract

Section: Summary and Disccssionmentioning

confidence: 99%